Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Operations (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Cash from Operations for 9 consecutive years, with 31129000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 797.02% to 31129000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 67992000.0, a 267.22% increase, with the full-year FY2025 number at 67992000.0, up 267.22% from a year prior.
  • Cash from Operations was 31129000.0 for Q4 2025 at Akebia Therapeutics, up from 28105000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 33805000.0 in Q3 2022 to a low of 70746000.0 in Q1 2021.
  • A 5-year average of 16108500.0 and a median of 11826500.0 in 2024 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 377.38% in 2024, then surged 797.02% in 2025.
  • Akebia Therapeutics' Cash from Operations stood at 62808000.0 in 2021, then grew by 12.94% to 54679000.0 in 2022, then soared by 95.78% to 2308000.0 in 2023, then plummeted by 93.5% to 4466000.0 in 2024, then soared by 797.02% to 31129000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Cash from Operations are 31129000.0 (Q4 2025), 28105000.0 (Q3 2025), and 22345000.0 (Q2 2025).